Previous 10 | Next 10 |
BOSTON, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten public offering of 1,905,000 shares of its commo...
Albireo Pharma (NASDAQ: ALBO ) is down 3% in light trading after hours after proposing a public offering of common stock. More news on: Albireo Pharma, Inc., Healthcare stocks news, Stocks on the move, Read more ...
BOSTON, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it has commenced a proposed underwritten public offering of its common stock. In connection with...
— Reiterates Top Line Data on Phase 3 in PFIC Expected Mid-2020 — — To Initiate Pivotal Trials in Biliary Atresia and Alagille Syndrome in 2020 — BOSTON, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-...
BOSTON, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, commemorates the first International Alagille Awareness Day on January 24, 2020, acknowledging pediatric hepatol...
BOSTON, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present at the Jefferies 2019 Londo...
Albireo Pharma, Inc. (ALBO) Q3 2019 Earnings Conference Call November 6, 2019 10:00 AM ET Company Participants Paul Arndt - LifeScience Advisors Ron Cooper - President and Chief Executive Officer Simon Harford - Chief Financial Officer Patrick Horn - Chief Medical Officer Pam...
Image source: The Motley Fool. Albireo Pharma, Inc. (NASDAQ: ALBO) Q3 2019 Earnings Call Nov 6, 2019 , 10:00 a.m. ET Operator Continue reading
Albireo Pharma (NASDAQ: ALBO ): Q3 GAAP EPS of -$1.73 misses by $0.17 . More news on: Albireo Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
— Phase 3 PFIC trial randomization more than three-quarters complete. — — Topline results expected mid-2020. — — Pivotal trial in biliary atresia expected to be initiated in 2020. — — Management to host conference ca...
News, Short Squeeze, Breakout and More Instantly...
Albireo Pharma Inc. Company Name:
ALBO Stock Symbol:
NASDAQ Market:
Bylvay (odevixibat) granted Priority Review by U.S. FDA ASSERT study demonstrated efficacy of Bylvay in pruritus, bile acids and sleep with a low drug-related diarrhea rate in Alagille patients Approval in second indication would more than double Bylvay market oppo...
Two somewhat under-the-radar biotech companies saw their share prices soar this week after agreeing to be acquired. CinCor Pharma (NASDAQ: CINC) is being bought out by deep-pocketed pharmaceutical company AstraZeneca , while Albireo Pharma (NASDAQ: ALBO) is set to be owned by ...
The Nasdaq Composite (NASDAQINDEX: ^IXIC) might finally be looking to gain some momentum in 2023, with investors desperately wanting a reversal from 2022's horrible performance. Sizable gains on Friday helped to build more positive sentiment, and the bullish move continued on Monday morni...